New Haven, Connecticut and St.
Louis, Missouri
March 9, 2005
Aim is to improve soybeans
An agreement between
Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC),
Monsanto Company (NYSE:
MON) and the Agricultural Research Service (ARS), the chief
scientific research agency of the U.S. Department of Agriculture
(USDA), is expected to provide U.S. soybean plant breeders with
new technology for more accurate and efficient plant breeding
research.
The project’s
intent is to map single nucleotide polymorphism (SNP) DNA
markers in soybeans, creating a detailed molecular genetic map
of the soybean that includes a large number of SNP DNA markers
along with pre-existing SSR (simple sequence repeat) markers. In
addition, all of the map position information and use of soybean
SNP markers covered by the agreement will be freely available to
all U.S. soy breeders and geneticists, creating the first
publicly available map of its kind.
A SNP is a specific location along a chromosome where there is a
variation in the genetic sequence. This variation can be used as
a genetic marker. Scientists often use genetic markers as a tag
to identify the specific location of a genetic trait on a
chromosome. By tagging the desired trait, plant breeders can
breed plants more efficiently and more accurately.
“Monsanto is proud to be a part of this important research
initiative,” said Monsanto’s Global Genotyping Lead Robert
Reiter. “We hope that our work with Genaissance and the USDA
will lead to a better understanding of the soybean, and help
develop ways to deliver improved soybean varieties faster and
more efficiently, putting new technology into the hands of
public soy researchers.”
The collaborators plan to make the information available in
Soybase, the USDA Soybean Genome Database, and dbSNP, the
National Center for Biotechnology Information SNP database, as
well as publish the information in scientific journals, so plant
breeders have access to the important data.
The SNPs that are being mapped were discovered at the USDA, ARS
Beltsville, Md., with support from the United Soybean Board.
“Because all of the SNPs are located in genes, the result of the
work will be a genetic map that defines ‘gene-rich regions’ of
the soybean genome,” said Perry Cregan, USDA-ARS researcher. “It
is the gene-containing regions that are of greatest interest to
soybean breeders and geneticists who want to develop genetically
superior soybean varieties with enhanced seed quality, greater
disease resistance, and superior drought tolerance and yield.”
"What we learn from this research will be
critical in our search for additional insights into ways to
improve the characteristics, production rates, and disease
resistance of a variety of field crops, including soybeans, and
other plant species," said Gerald F. Vovis, Ph.D., Executive
Vice President and Chief Technology Officer of Genaissance
Pharmaceuticals.
ARS scientists
in Beltsville, Maryland, discovered the soybean SNPs and saw
value for public researchers in having the SNPs mapped. As part
of the agreement, Monsanto will provide funding to support the
mapping, which Genaissance will perform, given its expertise as
a SNP genotyping services provider.
Today’s announcement builds on previous announcements that
target public sector research.
Genaissance Pharmaceuticals, Inc. is developing innovative
products based on its proprietary pharmacogenomic technology and
has a revenue-generating business in DNA and pharmacogenomic
products and services. Genaissance also markets its proprietary
FAMILION™ Test, designed to detect mutations responsible for
causing Familial Long QT and Brugada Syndromes, two causes of
sudden cardiac death. The company's product development
strategy is focused on drug candidates with promising clinical
profiles and finding genetic markers to identify a responsive
patient population. This strategy enables Genaissance to
leverage existing clinical data and, thus, reduce the costs and
risks associated with traditional drug development and increase
the probability of clinical success and commercialization.
Monsanto Company (NYSE: MON) is a leading global
provider of technology-based solutions and agricultural products
that improve farm productivity and food quality. |